XLH-Disease Monitoring Program (DMP)

Condition: X-Linked Hypophosphatemia (XLH)

Type of Research: Observational
Principal Investigator: Eric Gyuricsko, MD
Primary Study Coordinator: Erin McAndrews, LPN

Study Specifications: XLH (Rickets) is a rare, chronic genetic disorder that represents an unmet medical need. Burosumab (Crysvita®) met FDA approval in 2018 for adult and pediatric patients over the age of one. XLH-DMP is a long-term study aiming to collect pertinent information on adult and pediatric patients with XLH that have/have not participated in Burosumab clinical trials. XLH-DMP aims to monitor patients for 10 years, to assess the safety and efficacy of Burosumab while also monitoring the progression of XLH without treatment.

Point of Contact for the Study: Erin McAndrews LPN
Phone: (757) 668-6896